Summary.-The anti-tumour action of methylene dimethane sulphonate (MDMS) has been further investigated in relation to its immunosuppressive properties. Following a dose of 10 mg/kg, the proportion of permanent regressions of Yoshida lymphosarcoma transplants is lower in animals treated during the first 5 days of tumour growth. Re-implants on day 28 to those animals in which regression of the tumour had occurred indicated that the immune response to the tumour increases during the first 7 days of tumour growth.
METHYLENE dimethane sulphonate (MDMS) has been shown (Fox and Jackson, 1965; Fox, 1969) to exert an excellent anti-tumour action on the transplanted Yoshida lymphosarcoma in the Wistar rat. This tumour is equivalent to an allograft system, but the host reaction against the transplantation antigens, although great, does not normally reject the tumour which eventually kills the animal. Although tumour-specific antigens probably play a minor role in determining the host reaction against it, this system does provide a useful model system to study the contribution of host immunity to the chemotherapeutic effect of an anti-tumour drug (Mihich, 1969) . The factors influencing drug-induced remission have been reviewed by Goldin (1969) and Mandel and Rall (1969) .
The results of the present study indicate that the effectiveness of MDMS as an anti-tumour agent varies according to the level of immunity developed in the tumour-bearing host. We have also found that MDMS like other members of this series of bifunctional alkylating agents (Berenbaum, Timmis and Brown, 1967) possesses immunosuppressive properties as well as tumour cytotoxicity and the net effect of these two opposing activities in terms of tumour regression, depends on the time of MDMS administration relative to the time of tumour transplantation.
MATERIALS AND METHODS
Methylene dimethane sulphonate was prepared as previously described (Fox and Jackson, 1965) and injected intraperitoneally in physiological saline (2-5 mg/ml). All solutions were prepared under chilled conditions immediately before use to avoid breakdown of the drug due to hydrolysis.
For the tumour growth studies, female Wistar rats (150-200 g, 8 fed on a standard diet based on the Scottish N.E. Agricultural Society recommendations and water ad libitum were used. Small pieces of tumour tissue (approximately 5 mm 3) were transplanted subcutaneously by trochar implantation into the flank of the animal. The tumour volume was measured as previously described (Fox, 1969) (Gregory and Lajtha, 1970 (Fig. 1) . However, only those animals that showed no regrowth of the tumour following the initial regression were used in the construction of this figure. The number of animals in each group excluded because of tumour regrowth is indicated in Table I (Part 1). It can be seen that, paradoxically, animals treated 3 days after transplantation were less likely to show complete regression of their tumours than animals with much larger tumours (up to more than 10 times larger) treated on the 5th to 9th day. To determine whether this variation in the effectiveness of MDMS treatment could be related to a corresponding variation in the level of the anti-tumour immunity developed in the host, the tumour-free survivors in each group were tested for their ability to reject a second Yoshida tumour transplanted 28 days after receiving the first transplant. Only 36% of the animals whose initial tumours were allowed to grow for 3 days prior to MDMS treatment were sufficiently sensitized to prevent a second transplant from becoming even temporarily established (Table I , Part 2). Part 2 shows the situation following the rechallenge of those animals in Part 1 in which the tumour had regressed. " Progressive " tumours are those which continued to grow nearly exponentially and " delayed regressive " tumours are those which first grow to measurable volumes and within 2 to 3 weeks decrease and disappear.
Part 3 shows the situation following a second reimplant of those animals in Part 2 in which the first reimplant had regressed.
Longer exposure to the primary sensitizing tumour prior to MDMS administration resulted in an increasing percentage of animals " immune " to the second transplant.
Further challenge of these " immune animals 4-5 months later revealed the longevity of this anti-tumour immunity; however, differences between the resistant survivors of the first re-implants were not detectable (Table I, Fig. 2 . We have consistently observed that the general pattern of the PFC response in MDMS treated mice remains relatively unchanged, although the peak of the response may be depressed (about 78% in the experiment shown in Fig. 2 ) and may also be delayed depending on the extent of immunosuppression. the dose response curve obtained. Using the LD 50/30 dose as a basis for comparison, MDMS is virtually indistinguishable from x-rays in its immunosuppressive activity (Gregory and Ebert, 1971) . It is unlikely that the development of anti-tumour immunity in rats implanted with Yoshida tumours would be affected by MDMS in exactly the same way as the PFC response of mice to a single injection of sheep red cells. It seemed reasonable, however, to expect that some suppression would occur and as a result cause tumours implanted after drug treatment to grow faster than normal. effect of MDMS (20 mg/kg) as a function of the interval between drug administration and immunization. In this experiment groups of mice were given MDMS at the times indicated and then injected all together at time zero with 108 sheep red cells. In each treatment group mice were assayed for PFC on days 3, 4, and 5, and the maximum count obtained during this period was used to calculate the per cent suppression (relative to untreated immunized controls). The greatest immunosuppressive effect was seen when MDMS was given close to the time of immunization.
On the basis of this study MDMS given 2 hours before immunization was selected as the schedule for measuring the effect of increasing doses of MDMS on the peak PFC response. of MDMS at earlier times had no detectable effect.
DISCUSSION
It is generally accepted that most if not all tumours possess antigens which may be recognized by the immunological system of the tumour-bearing host. Evidence that host-immune reactions may contribute in a significant way to the anti-tumour effectiveness of a given treatment has also been reported (Mihich, 1967 (Mihich, , 1969 . The likelihood of a similar explanation in the case of MDMS treated rats bearing Yoshida sarcoma transplants was suggested by the results of a previous study (Fox, 1969) which showed that permanent regression of well-established (20-30 g) Quinn, 1970) and differs markedly from other closely related members of the same series of dialkane sulphonates (Berenbaum et al., 1967) .
In view of the observed time dependence of the immunosuppressive activity of MDMS, the decreased effectiveness of MDMS treatment given 3 days rather than 5 or 7 days after transplantation may be exaggerated by a different immunosuppressive effect resulting from injection of the drug at these two different times on a developing immune system. Similarly, the acquisition by the rat of an increasing capacity to reject tumour cells following tumour transplantation might occur more rapidly than the data in Table I 
